Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.73 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895787 | 1.00 | EPHX1 (0.73) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL43428 | 1.00 | EPHX1 (0.73) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL8734599 | 0.98 | EPHX1 (0.70) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL8842804 | 0.98 | EPHX1 (0.70) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL17906518 | 0.87 | SLC6A4 (0.56) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL16945131 | 0.87 | SLC6A4 (0.56) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL8749872 | 0.87 | EPHX1 (0.55) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL6014598 | 0.85 | EPHX1 (0.53) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL28656 | 0.85 | EPHX1 (1.00) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL13696737 | 0.82 | LTA4H (0.72) | SLC6A2MAOASLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| WO-2024054618-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-110628739-B | Amine dehydrogenase mutant and application thereof in synthesis of chiral amine and amino alcohol | 华东理工大学 | 2021-04-09 | — | — | CN | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-0404146-B1 | Enantiomeric enrichment and stereoselective synthesis of chiral amines | CELGENE CORP (US) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | EPHX1 4200/4885ANPEP 696/4885SLC6A4 4316/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | EPHX1 1092/4885ANPEP 2051/4885SLC6A4 4197/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | EPHX1 4200/4885ANPEP 696/4885SLC6A4 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.